Abstract graphic of an eye
Investor Relations

Press Release

Harvard Bioscience Announces First Quarter 2024 Financial Results

May 7, 2024

Strong gross margin performance and focus on efficiency to support ongoing investments in growth

HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024.

Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of 60%. After quarter end, we announced a cost reduction initiative to improve our operating cost structure and support our ongoing investments in growth.”

Green continued, “Looking ahead, we are excited by our growth strategy and new product commercializations. Together with the new round of Chinese stimulus targeting a range of products including academic research and healthcare products, we continue to expect solid growth in the second half.”

Financial Results SummaryThree Months Ended March 31,
(unaudited, $ in millions except per share data) 2024   2023 
Revenues$24.5  $30.0 
Gross margin 60.3%   61.2% 
Operating (loss) income (GAAP)$(2.3)  $1.7 
Adjusted operating income$1.2  $4.4 
Net (loss) income (GAAP)$(4.7)  $0.6 
Diluted (loss) earnings per share (GAAP)$(0.11)  $0.01 
Diluted adjusted earnings per share$0.02  $0.06 
Adjusted EBITDA$1.6  $4.8 
Adjusted EBITDA margin 6.6%   15.9% 
Cash flow provided by operations$1.4  $1.8 

This press release includes certain financial information presented on an adjusted, or non-GAAP, basis. For additional information on the non-GAAP financial measures included in this press release, please see “Use of Non-GAAP Financial Information” and “Reconciliation of GAAP to Non-GAAP Financial Measures” below.

First Quarter 2024 Results

For the first quarter of fiscal 2024, the Company reported revenues of $24.5 million compared to $30.0 million in the first quarter of fiscal 2023. Gross margin for the three months ended March 31, 2024 was 60.3% compared with 61.2% in the comparable quarter of the prior year.

Net loss for the first quarter of 2024 was $(4.7) million which included a loss on marketable securities and other operating expenses of approximately ($2.3) million. This compares to net income of $0.6 million in the first quarter of 2023. Adjusted EBITDA for the first quarter of 2024 was $1.6 million, compared to $4.8 million in the first quarter of the prior year.

Cash provided by operations for the first quarter of 2024 was $1.4 million compared to $1.8 million in the same period last year. Debt was reduced by $1.0 million during the first quarter of 2024.

2024 Guidance

For the full year 2024 we expect revenues to be approximately flat versus 2023. We expect second half growth versus both first half of 2024 and second half of 2023, supported by new product commercializations and expected improvements in China. We also continue to expect 2024 gross margin of approximately 60% and adjusted EBITDA margin in the mid-teens.

Webcast and Conference Call Details

In conjunction with this announcement, Harvard Bioscience will be hosting a conference call and webcast today at 8:00 a.m. Eastern Time. A presentation that will be referenced during the webcast will be posted to our Investor Relations website shortly before the webcast begins.

Analysts who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here.

Use of Non-GAAP Financial Information

In this press release, we have included non-GAAP financial information, including one or more of adjusted operating income (loss), adjusted operating margin, adjusted net income (loss), adjusted EBITDA, adjusted EBITDA margin, adjusted diluted earnings (loss) per share, and net debt. We believe that this non-GAAP financial information provides investors with an enhanced understanding of the underlying operations of the business. For the periods presented, these non-GAAP financial measures have excluded certain expenses and income resulting from items that we do not believe are representative of the underlying operations of the business. Items excluded include stock-based compensation, amortization of intangibles related to acquisitions, other operating expenses, loss on equity securities, income taxes, and the tax impact of the reconciling items. Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.

Non-GAAP historical financial statement information included herein is accompanied by a reconciliation to the nearest corresponding GAAP measure which is included as exhibits below in this press release.

With respect to non-GAAP forward-looking measures, we provide an outlook for adjusted EBITDA margin. Many of the items that we exclude from this forward-looking measure calculation are less capable of being controlled or reliably predicted by management. These items could cause the forward-looking measures presented in our outlook statements to vary materially from our GAAP results.

The non-GAAP financial information provided in this press release should be considered in addition to, not as a substitute for, the financial information provided and presented in accordance with GAAP and may be different than other companies’ non-GAAP financial information.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions or statements that do not relate to historical matters. Forward-looking statements include, but are not limited to, information concerning expected future financial and operational performance including revenues, gross margins, earnings, cash and debt position, growth and the introduction of new products, and the strength of the Company’s market position and business model. Forward-looking statements are not guarantees of future performance and involve known and unknown uncertainties, risks, assumptions, and contingencies, many of which are outside the Company’s control. Risks and other factors that could cause the Company’s actual results to differ materially from those described its forward-looking statements include those described in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K as well as in the Company’s other filings with the Securities and Exchange Commission. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this document. Except as required by law, the Company assumes no obligation to update forward-looking statements to reflect any change in expectations, even as new information becomes available.

Company Contact:
Jennifer Cote
Chief Financial Officer
(508) 893-3120

Investors Contact:
Three Part Advisors
Sandy Martin / Erol Girgin / William Shelmire
(214) 616-2207

Consolidated Statements of Operations
(unaudited, in thousands, except per share data)
   Three Months Ended 
    March 31, 2024  March 31, 2023 
 Revenues$24,512  $29,975  
 Cost of revenues 9,740   11,629  
  Gross profit 14,772   18,346  
 Operating expenses:      
  Sales and marketing expenses 5,904   5,978  
  General and administrative expenses 5,963   6,334  
  Research and development expenses 2,885   2,897  
  Amortization of intangible assets 1,333   1,388  
  Other operating expenses 966   -  
 Total operating expenses 17,051   16,597  
 Operating (loss) income (2,279)  1,749  
 Other (expense) income:      
  Interest expense (751)  (974) 
  Loss on equity securities (1,312)  -  
  Other (expense) income, net (142)  432  
 Total other expense (2,205)  (542) 
 (Loss) income before income taxes (4,484)  1,207  
 Income tax expense 210   585  
 Net (loss) income$(4,694) $622  
 (Loss) income per common share:      
  Basic$(0.11) $0.01  
  Diluted$(0.11) $0.01  
 Weighted-average common shares:      
  Basic 43,402   42,119  
  Diluted 43,402   42,783  

Condensed Consolidated Balance Sheets
(unaudited, in thousands)
  March 31, 2024 December 31, 2023 
 Cash and cash equivalents$4,255 $4,283 
 Accounts receivable, net 15,309  16,099 
 Inventories 24,136  24,716 
 Other current assets 4,448  3,940 
 Total current assets 48,148  49,038 
 Property, plant and equipment 4,492  3,981 
 Goodwill and other intangibles 71,377  73,101 
 Other long-term assets 9,144  11,246 
 Total assets$133,161 $137,366 
 Liabilities and Stockholders' Equity      
 Current portion, long-term debt$3,720 $5,859 
 Other current liabilities 21,957  20,683 
 Total current liabilities 25,677  26,542 
 Long-term debt, net 31,890  30,704 
 Other long-term liabilities 6,782  7,046 
 Stockholders’ equity 68,812  73,074 
 Total liabilities and stockholders’ equity$133,161 $137,366 

Condensed Consolidated Statements of Cash Flows 
(unaudited, in thousands)  
  Three Months Ended 
   March 31, 2024  March 31, 2023 
 Cash flows from operating activities:      
 Net (loss) income$(4,694) $622  
 Adjustments to operating cash flows 4,389   2,486  
 Changes in operating assets and liabilities 1,708   (1,296) 
 Net cash provided by operating activities 1,403   1,812  
 Cash flows from investing activities:      
 Additions to property, plant and equipment (645)  (224) 
 Acquisition of intangible assets (75)  -  
 Proceeds from sale of product line -   512  
 Proceeds from sale of marketable equity securities 495   -  
 Net cash (used in) provided by investing activities (225)  288  
 Cash flows from financing activities:      
 Borrowing from revolving line of credit 2,500   1,500  
 Repayment of revolving line of credit (500)  (2,500) 
 Repayment of term debt (3,023)  (1,841) 
 Proceeds from exercise of employee stock options and purchases 15   104  
 Taxes paid related to net share settlement of equity awards (47)  (156) 
 Net cash used in financing activities (1,055)  (2,893) 
 Effect of exchange rate changes on cash and cash equivalents (151)  74  
 Decrease in cash and cash equivalents (28)  (719) 
 Cash and cash equivalents at the beginning of period 4,283   4,508  
 Cash and cash equivalents at the end of period$4,255  $3,789  

 Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
 (in thousands, except per share data and percentages)
   Three Months Ended 
   March 31, 2024 March 31, 2023 
 GAAP operating (loss) income$ (2,279) $ 1,749  
  Stock-based compensation 1,048   1,153  
  Acquired asset depreciation & amortization 1,339   1,401  
  Other operating expenses (1) 966   -  
  Other adjustments 97   131  
 Adjusted operating income$ 1,171  $ 4,434  
 Operating margin (9.3%)  5.8% 
 Adjusted operating margin 4.8%  14.8% 
 GAAP net (loss) income$ (4,694) $ 622  
  Stock-based compensation 1,048   1,153  
  Acquired asset depreciation & amortization 1,339   1,401  
  Other operating expenses (1) 966   -  
  Other adjustments 97   131  
  Gain on sale of product line and dividend income -   (493) 
  Loss on equity securities 1,312   -  
  Income taxes 627   (340) 
 Adjusted net income 695   2,474  
  Depreciation & amortization 443   321  
  Interest and other expense, net 893   1,036  
  Adjusted income taxes (2) (417)  924  
 Adjusted EBITDA$ 1,614  $ 4,755  
 Adjusted EBITDA margin 6.6%  15.9% 
 Diluted (loss) earnings per share (GAAP)$ (0.11) $ 0.01  
 Diluted adjusted earnings per share$ 0.02  $ 0.06  
 Weighted-average common shares:    
  Diluted GAAP 43,402   42,783  
  Diluted Adjusted 44,693   42,783  
  (1) Other operating expenses include a $0.5 million commission fee paid in connection with the receipt of employee retention credits and an estimated loss of $0.5 million related to an unclaimed property audit. 
  (2) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise. 

 Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)
 (in thousands)
  March 31, 2024 December 31, 2023
  March 31, 2023 
 Debt, including unamortized deferred financing costs $ 35,610  $ 36,563  $ 44,053  
 Unamortized deferred financing costs 490   560   770  
 Cash and cash equivalents (4,255)   (4,283)   (3,789)  
 Net debt $ 31,845  $ 32,840  $ 41,034